Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2020

View Archived Issues

Novel variant linked to childhood steroid-sensitive nephrotic syndrome

HanaVax, University of Tokyo present mutated Pneumococcal surface proteins

New CD73 inhibitors synthesized at Eternity Bioscience

J2H Biotech, Ahn-Gook Pharmaceutical describe new mirabegron prodrugs

University of Florida identifies new PRMT5 inhibitors

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical patent ERK-1/2 inhibitors

Dimerix announces positive data from phase II ACTION trials of DMX-200 in kidney disease

Global phase III PolarisDMD trial of edasalonexent does not meet primary endpoint

XL-092: a promising pan-tyrosine kinase inhibitor in clinical development

First patient enrolled in the immune modulation domain of REMAP-COVID substudy

Prilenia initiates enrollment in phase III PROOF-HD trial of pridopidine

New phase I/Ib study to evaluate GEN-001 with avelumab for solid tumors

Positive 6-month interim analysis data presented from TOPAZ phase II study of SRK-015

Alzheon studies ALZ-801 in phase II biomarker study for early Alzheimer's

UKRI conditionally approves grant funding to explore SDC-1801 as treatment of COVID-19

SIMR-1281: a novel candidate for clinical trials in cancer

ASHG 2020: New inflammatory disease, and maybe, a new classification system

First-in-human data presented for TPX-0022

FDA clears IND for phase Ib study of bempegaldesleukin for COVID-19

Spero Therapeutics' SPR-720 shows promise in phase I study

Voclosporin studied for antiviral effects in kidney transplant recipients with COVID-19

Apollomics reports phase I data for APL-101

FDA approves Eysuvis for short-term treatment of dry eye disease

Valo Therapeutics describes design and preclinical results with neoantigen-coated oncolytic viruses

Novel selective TRK degraders effectively reduce TPM3-TRKA fusion protein levels

New pilot study to evaluate afamelanotide for arterial ischemic stroke

Histogen and Amerimmune collaborate to study emricasan for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...